RxDoctor Payments Data

Tonda Jackson

Family · Columbia, SCNPI 1184690174

Payments from drug & device makers

$2,122in general payments, 2019–2025

Across 78 payments — averaging $27.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$1K
  • Janssen Products, LP$249
  • Janssen Scientific Affairs, LLC$191
  • Theratechnologies Inc.$179
  • Gilead$153
  • Johnson & Johnson$119
  • plus $190 from 3 others

What the payments were for

  • Food & beverage$1,80885%
  • Education$31415%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,122 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$4,299
Medicare patients
12
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala98$375,801
DovatoDolutegravir Sodium/Lamivudine100$281,998
GenvoyaElviteg/Cob/Emtri/Tenof Alafen66$261,040
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf32$150,071
TivicayDolutegravir Sodium34$104,186
DescovyEmtricitabine/Tenofov Alafenam47$100,756
PifeltroDoravirine24$42,486
TriumeqAbacavir/Dolutegravir/Lamivudi11$38,077
PrezcobixDarunavir/Cobicistat12$30,193
Isentress HdRaltegravir Potassium12$24,001
OzempicSemaglutide14$13,292
TrulicityDulaglutide12$10,927
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,175
FarxigaDapagliflozin Propanediol12$7,241
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$6,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$153$737,597211 claims
Viiv Healthcare CompanyDovato, Tivicay, Triumeq$1,040$424,262145 claims
Janssen Products, LPSymtuza$249$150,07132 claims
MerckPifeltro, Isentress Hd, Janumet$103$69,78949 claims
Johnson & JohnsonPrezcobix$119$30,19312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.

Other family in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →